Payment overview · 2025
General Payments
$180.35
7 reported records · 5 companies
Healthcare provider profile · identity verified
Roberto Gonzalez, MD
Allopathic & Osteopathic Physicians|Internal Medicine · EL PASO, TX · NPI 1891159349
Verified facts
What the public records show
CMS Open Payments records show Roberto Gonzalez, MD received $180.35 in general payments during 2025 across 7 reported records.
Abbott Laboratories accounted for 38.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENBREL as an associated drug or biological on 9330 records involving 2094 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Enbrel by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Prolia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 239 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $69.76 | 38.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $60.94 | 33.8% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.80 | 11.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.11 | 8.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.74 | 7.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $180.35 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $81.74 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $69.76 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.11 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.11 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 95 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ENBREL open payments reported associated product |
CMS Open Payments — General Payments 9330 supporting records · 2094 recipient NPIs · example record 1226877474 |
Enbrel · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
43 | 28 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
95 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
95 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
239 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
74 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 808 | 260 |
| Levothyroxine Sodium | Levothyroxine Sodium | 504 | 144 |
| Gabapentin | Gabapentin | 455 | 153 |
| Lisinopril | Lisinopril | 449 | 135 |
| Metformin Hcl Er | Metformin Hcl | 435 | 132 |
| Amlodipine Besylate | Amlodipine Besylate | 416 | 130 |
| Pioglitazone Hcl | Pioglitazone Hcl | 373 | 110 |
| Losartan Potassium | Losartan Potassium | 340 | 103 |
| Omeprazole | Omeprazole | 315 | 101 |
| Carvedilol | Carvedilol | 264 | 80 |
| Clonazepam | Clonazepam | 261 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 241 | 84 |
| Mounjaro | Tirzepatide | 239 | 35 |
| Ozempic | Semaglutide | 236 | 45 |
| Finasteride | Finasteride | 220 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 219 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 201 | 68 |
| Famotidine | Famotidine | 196 | 81 |
| Hydrochlorothiazide | Hydrochlorothiazide | 183 | 58 |
| Montelukast Sodium | Montelukast Sodium | 180 | 61 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 175 | 23 |
| Simvastatin | Simvastatin | 175 | 51 |
| Tramadol Hcl | Tramadol Hcl | 175 | 42 |
| Trazodone Hcl | Trazodone Hcl | 175 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 168 | 61 |
| Farxiga | Dapagliflozin Propanediol | 158 | 55 |
| Ezetimibe | Ezetimibe | 156 | 49 |
| Metformin Hcl | Metformin Hcl | 150 | 47 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 147 | 75 |
| Alendronate Sodium | Alendronate Sodium | 145 | 67 |
| Diclofenac Sodium | Diclofenac Sodium | 142 | 53 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 137 | 37 |
| Hydralazine Hcl | Hydralazine Hcl | 136 | 46 |
| Zolpidem Tartrate | Zolpidem Tartrate | 127 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 121 | 57 |
| Pravastatin Sodium | Pravastatin Sodium | 113 | 32 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 111 | 42 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 98 | 25 |
| Jardiance | Empagliflozin | 95 | 31 |
| Meclizine Hcl | Meclizine Hcl | 95 | 42 |
| Lorazepam | Lorazepam | 85 | 19 |
| Pregabalin | Pregabalin | 84 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 83 | 27 |
| Alprazolam | Alprazolam | 82 | 13 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 81 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 80 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 79 | 25 |
| Furosemide | Furosemide | 74 | 33 |
| Trulicity | Dulaglutide | 74 | 18 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 73 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 73 | 23 |
| Dicyclomine Hcl | Dicyclomine Hcl | 68 | 38 |
| Glipizide Er | Glipizide | 68 | 22 |
| Januvia | Sitagliptin Phosphate | 68 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 24 |
| Eliquis | Apixaban | 66 | 22 |
| Raloxifene Hcl | Raloxifene Hcl | 63 | 21 |
| Clotrimazole | Clotrimazole | 59 | 31 |
| Valsartan | Valsartan | 59 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | 16 |
| Glipizide | Glipizide | 57 | 20 |
| Lactulose | Lactulose | 56 | 23 |
| Linzess | Linaclotide | 56 | 13 |
| Rybelsus | Semaglutide | 56 | 23 |
| Synthroid | Levothyroxine Sodium | 56 | 15 |
| Vascepa | Icosapent Ethyl | 52 | 16 |
| Memantine Hcl | Memantine Hcl | 47 | 16 |
| Allopurinol | Allopurinol | 46 | 17 |
| Repatha Pushtronex | Evolocumab | 46 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 45 | 24 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 44 | 40 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | 12 |
| Prolia | Denosumab | 43 | 28 |
| Azelastine Hcl | Azelastine Hcl | 41 | 27 |
| Azithromycin | Azithromycin | 39 | 33 |
| Spironolactone | Spironolactone | 38 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 38 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 37 | 14 |
| Invokana | Canagliflozin | 35 | suppressed |
| Lidocaine | Lidocaine | 34 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | 14 |
| Sertraline Hcl | Sertraline Hcl | 33 | 11 |
| Tymlos | Abaloparatide | 33 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | 14 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 32 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 32 | 32 |
| Topiramate | Topiramate | 32 | suppressed |
| Mirtazapine | Mirtazapine | 31 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 31 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Repatha Sureclick | Evolocumab | 27 | 11 |
| Ondansetron Odt | Ondansetron | 26 | 19 |
| Cefdinir | Cefdinir | 25 | 22 |
| Dutasteride | Dutasteride | 25 | suppressed |
| Enbrel | Etanercept | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | 11 |
| Prednisone | Prednisone | 24 | 17 |
| Memantine Hcl Er | Memantine Hcl | 23 | suppressed |
| Tradjenta | Linagliptin | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Potassium Chloride | Potassium Chloride | 22 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Celecoxib | Celecoxib | 21 | 18 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 21 | 15 |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Gemtesa | Vibegron | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Probenecid | Probenecid | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 11 |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | 12 |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | 13 |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Glyburide | Glyburide | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Ativan | Lorazepam | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Meloxicam | Meloxicam | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Azathioprine | Azathioprine | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | 11 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $180.35 · 7 records | Abbott Laboratories | Cologuard Collection Kit, FREESTYLE LIBRE 3, JARDIANCE, OTEZLA, REPATHA | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error